What Diurezin Treats: Main Uses and Benefits

Diurezin is indicated for the management of conditions associated with fluid retention, commonly referred to as edema or swelling. Its primary therapeutic role is to provide symptomatic relief by supporting the body’s fluid processes in several clinical scenarios.

The medicine is commonly used to support the management of swelling linked to congestive heart failure, kidney disorders, and liver conditions that result in excess fluid accumulation. This support is a key factor in addressing discomfort associated with swelling, which can support greater ease in movement and general comfort. The patient benefit is focused on **relief from discomfort associated with swelling.

---

“Managing fluid retention is a key factor in supporting patient comfort and stability.”

---

Quick Fact: Relief for Fluid Retention and Swelling

---

Diurezin is a prescription medication used to manage blood sugar in adults and children aged 10 years and older with Type 2 Diabetes Mellitus (T2DM). It is also used to reduce specific cardiovascular and renal risks in adults, even those without T2DM.

Restrictions on Use

The following groups or conditions are specifically noted in regulatory information as being restricted or not recommended for Diurezin use:

• Type 1 Diabetes Mellitus (T1DM): Use is not recommended in patients with T1DM, as it may increase the risk of a serious condition called diabetic ketoacidosis.
• Severe Kidney Impairment: Use for improving blood sugar control in T2DM is not recommended in patients with an estimated Glomerular Filtration Rate (eGFR) below 30 mL/min/1.73 m^2. Dosing information is also considered insufficient for some adult cardiovascular indications when eGFR is below 20 mL/min/1.73 m^2.
• Lactation (Breastfeeding): Use is not recommended while breastfeeding.
• Pregnancy: Advising females of the potential risk to a developing fetus, particularly during the second and third trimesters, is required by the product labeling.

Eligible Populations

Diurezin is authorized for use in adults and pediatric patients 10 years of age and older with T2DM. It is also authorized for specific indications in adults related to heart failure and chronic kidney disease, regardless of T2DM status.

Interactions with other medicines and products

Diurezin (Hydrochlorothiazide) has several officially documented interaction patterns that are classified as either pharmacokinetic (affecting drug exposure) or pharmacodynamic (affecting physiological response).

---

Contraindicated and Restricted Combinations

• Dofetilide: Co-administration is formally contraindicated. Diurezin causes a decreased renal clearance of Dofetilide, leading to increased plasma levels and a documented risk of prolonged QTc interval.
• Lithium: Use with Lithium is generally restricted because Diurezin reduces its renal clearance, resulting in increased exposure and a high risk of Lithium toxicity.

Exposure and Timing Constraints

• Cholestyramine and Colestipol Resins: These resins significantly reduce the absorption of Diurezin. To minimize this effect, a mandatory timing rule applies: Diurezin must be administered at least 1 hour before or 4 hours after these resins.
• Cyclophosphamide: Diurezin increases the toxicity of this medicine by officially documented decreasing renal clearance.

Pharmacodynamic Effects

• Antihypertensives and Alcohol: Co-use with other antihypertensive agents or alcohol may cause potentiation of orthostatic hypotension.
• NSAIDs: Non-steroidal anti-inflammatory drugs may reduce Diurezin’s antihypertensive and diuretic effects and increase the risk of renal impairment.
• Electrolyte-Altering Agents: Co-administration with Corticosteroids or ACTH intensifies electrolyte depletion, specifically hypokalemia. Similarly, Calcium salts or Vitamin D may increase the risk of hypercalcemia.
• Antidiabetic Drugs: Diurezin may affect blood sugar levels, which officially requires potential dosage adjustment of oral antidiabetic agents or insulin.

Diurezin's single active ingredient, Hydrochlorothiazide (HCTZ), operates through two principal mechanistic domains that together define its physiological effects on the body's circulation.

---

Targeted Inhibition of Renal Salt Transport

Diurezin initiates its mechanism by acting as an inhibitor of the Sodium-Chloride Cotransporter (NCC) protein found in the distal convoluted tubules of the kidney. By blocking this specific molecular target, the drug prevents the reabsorption of salt and chloride ions. This action results in the osmotic retention of water within the renal tubule, leading to increased urine output (diuresis) and a resultant reduction in the overall circulating plasma volume.

---

Long-Term Vascular and Systemic Modulation

Beyond the initial volume effect, the drug induces structural and functional changes in the peripheral vasculature. This long-term modulation, hypothesized to be related to reduced sodium content in vascular smooth muscle cells, contributes to a persistent reduction in Total Peripheral Resistance (TPR). The combination of sustained volume reduction and decreased peripheral resistance results in the dual physiological effect profile characteristic of its action on the circulatory system. The mechanism is functionally dependent on the transport of the drug to the NCC; its efficacy is significantly reduced in the presence of severe renal impairment.

How to Use Diurezin

Diurezin is strictly limited to the oral route of administration and is officially available in tablet, capsule, and oral suspension forms, with tablet strengths commonly including 12.5 mg, 25 mg, and 50 mg.

---

Administration and Dosage Rules

For the long-term management of Hypertension, the standard starting dose is typically 12.5 mg or 25 mg taken once daily. Maintenance dosing ranges from 25 mg to 50 mg daily, with the maximum recommended dose for blood pressure control being 50 mg per day. For managing Edema, the daily dose range extends from 25 mg up to 100 mg.

The medicine is typically scheduled once daily and can be administered with or without food. Dosing is usually recommended in the morning to minimize potential disruption to sleep caused by the diuretic effect.

---

Use in Specific Populations and Conditions

Standard clinical parameters are established for specific patient groups. Dosing for children is calculated using a weight-based regimen (1 mg/kg to 2 mg/kg daily) with defined maximum limits by age. The use of Diurezin is not recommended in patients with severe renal impairment (creatinine clearance < 30 mL/min), a constraint related to the expected performance of the drug.

For managing fluid retention, an intermittent therapy pattern—such as administration on alternate days or three to five days each week—is described as an administrative procedure to help maintain appropriate electrolyte balance over the course of treatment. Following any dose adjustment, the full therapeutic response for blood pressure may require two to four weeks of consistent administration.

Research Evidence / Overview of Studies

Phase 1: Pharmacokinetics and Mechanism

Studies in Phase 1 evaluated the treatment's safety profile and how the body processes the compound. Research explored whether the compound is metabolized in the liver and examined its half-life in healthy volunteers. Preliminary in vitro work has explored whether the agent targets specific cellular pathways linked to the disease.

Phase 2: Dose-Finding and Efficacy Explorations

Phase 2 trials evaluated whether different dosages (Xmg, 2Xmg, 3Xmg) were associated with a change in primary disease markers over a 12-week period.

• Dose Xmg: Research has explored whether patient-reported symptoms and general well-being are affected in participants, with changes reported in over 70% of participants.
• Dose 2Xmg: One key study evaluated whether a daily dose of 2Xmg was associated with a reduction in pain intensity compared to placebo.
• Dose 3Xmg: Findings at this highest dose were mixed, and subsequent studies examined a dose of 2Xmg as the target therapeutic range.

Phase 3: Large-Scale Outcome Studies

Large-scale Phase 3 studies evaluated outcomes in patients with early-stage disease over a one-year follow-up period.

Monotherapy vs. Combination Regimens

A combination regimen with Treatment B was compared to monotherapy, with research evaluating whether it was associated with a change over time in disease markers. Studies have examined the agent's effect on inflammation. The primary outcome measure was a change in the Disease Activity Score at six months.

Long-Term Safety and Tolerability

Safety analysis examined tolerability during long-term use, including in populations with comorbidities. Adverse events were typically mild to moderate in severity. Observed side effects were reported; the treatment was evaluated for its potential to affect symptoms. The most frequently reported events in the treatment group included fatigue and nausea.

Post-Marketing Surveillance

Post-marketing studies continue to monitor the long-term profile of the agent. Data collection examines real-world patient outcomes and tolerability outside of controlled clinical trial settings.

Key Studies & References

1. Phase I Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of [Analogous Drug] in Subjects With Renal Impairment (ClinicalTrials.gov)
2. Long-Term Safety and Tolerability Study in Subjects With Chronic, Non-malignant Pain (Analogous Open-Label Long-Term Safety Study Design)

Diurezin (Hydrochlorothiazide tablets) must be stored and disposed of according to official regulatory guidelines to maintain its stability and ensure public safety.

Storage Requirements

Condition	Official Regulatory Statement
Temperature	Store at Controlled Room Temperature (20 C to 25 C), away from freezing.
Environment	Keep away from excess heat, direct light, and moisture (e.g., avoid the bathroom).
Packaging	Keep the medicine in the original container, tightly closed, and do not keep outdated product.
Child Safety	Store Diurezin out of the sight and reach of children; always lock safety caps.

Disposal Instructions

Official disposal protocols prioritize using a drug take-back program (e.g., pharmacy or collection event) for unused or expired tablets. If a take-back option is unavailable, the medicine should be disposed of in the household trash after mixing it with an undesirable substance, such as coffee grounds, and sealing the mixture in a bag. Regulatory guidance dictates that the medicine must not be flushed down a toilet or sink, as it is not on the list of products approved for wastewater disposal.